Table 1.
Baseline patient characteristics and treatment data.
| Variable | Level | Pre-treatment analysis set (N=230) |
Post-treatment analysis set (N=176) |
||
|---|---|---|---|---|---|
| Frequency | % | Frequency | % | ||
|
Age (yrs) Mean +/− Std dev Median (range) |
64.6 +/− 9.6 65 (36, 85) |
64.3 +/− 9.3 65 (36, 82) |
|||
| Gender | Male | 146 | 63.5% | 114 | 64.8% |
| Female | 84 | 36.5% | 62 | 35.2% | |
| Clinical stage | IIB | 8 | 3.5% | 6 | 3.4% |
| IIIA | 116 | 50.4% | 97 | 55.1% | |
| IIIB | 105 * | 45.7% | 73 * | 41.5% | |
| IV † | 1 | 0.4% | 0 | 0.0% | |
| Performance status | Fully active | 101 | 43.9% | 88 | 50.0% |
| Ambulatory, capable of light work |
129 | 56.1% | 88 | 50.0% | |
| Chemotherapy regimen | Carboplatin / Paclitaxel | 93 | 40.4% | 74 | 42.1% |
| Cisplatin / Etoposide | 34 | 14.8% | 29 | 16.5% | |
| Other | 89 | 38.7% | 73 | 41.5% | |
| Not initiated ** | 4 | 1.7% | 0 | 0.0% | |
| Data not available | 10 | 4.3% | 0 | 0.0% | |
| Radiotherapy | Evaluable patients Mean Dose +/− Std dev Median Dose (range) |
N=214 (93.0%) 64.5 Gy +/− 8.4 Gy 66 Gy (6 Gy, 79.2 Gy) |
N=174 (98.9%) 65.9 Gy +/− 4.3 Gy 66 Gy (56 Gy, 78 Gy) |
||
| Radiotherapy initiated, dose data not available |
2 | 0.9% | 1 | 0.6% | |
| Not initiated ** | 5 | 2.2% | 1 | 0.6% | |
| Data not available | 9 | 3.9% | 0 | 0.0% | |
*
There was 1 patient with stage III cancer, not further specified. This patient was included in the stage IIIB group for purposes of analysis.
†
One patient had oligometastatic stage IV disease. This patient was included in the IIIB group for purposes of analysis.
**
3 patients overlapped between the chemotherapy not initiated group and the radiotherapy not initiated group.